Subcutaneous efgartigimod significantly improves ocular myasthenia symptoms, with III ADAPT OCULUS data showing less double vision and drooping eyelids.
Eye specialists warn lid margin disease risks—often overlooked but linked to dry eye disease, chronic irritation, and vision instability.
Doctors report strong outcomes for gas-free macular hole surgery, eliminating gas tamponade and face-down positioning while maintaining high closure rates.